|
|
 |
| |
 How
effective is Gynazole·1 against Candida? |
| What
is bioadhesion? |
| How
is Gynazole·1 dosed? |
| How
fast does Gynazole·1 relieve symptoms? |
| Should
Gynazole·1 be taken at night to prevent leakage? |
| Which
Candida species is Gynazole·1 indicated for? |
| What
drug interactions are associated with Gynazole·1? |
| Is
there a risk of resistance to Gynazole·1? |
| |
| Q: How
effective is Gynazole·1 against Candida? |
|
A. |
In a clinical study, 94% of patients with vaginal yeast infections were
clinically cured 8–10 days post-treatment.* (1) |
|
| Q:
What is bioadhesion? |
|
A. |
Bioadhesion is the mechanism that enables Gynazole·1 to adhere to wet living
tissue for days and to deliver a targeted, continuous release of medication.
Bioadhesion is why Gynazole·1 is effective in treating a vaginal yeast
infection in a single dose that can be taken at any time.
Read more about how Gynazole·1 works. |
|
| Q:
How is Gynazole·1 dosed? |
|
A. |
Gynazole·1 offers the convenience of a single-dose yeast infection treatment.
The recommended dose of Gynazole·1 is one applicatorful of cream
(approximately 5 grams of the cream) intravaginally. This amount of cream
contains approximately 100 mg of butoconazole nitrate. |
|
| Q:
How fast does Gynazole·1 relieve symptoms? |
|
|
| Back
to top |
| Q:
Should Gynazole·1 be taken at night to prevent leakage? |
|
|
| Q:
Which Candida species is Gynazole·1 indicated for? |
|
A. |
Gynazole·1 is indicated for vulvovaginal candidiasis (VVC) caused by all
Candida species. On the other hand, Diflucan® and miconazole (the
active ingredient in Monistat®) may not be as effective against some common Candida
pathogens. (12,15) Click here to
learn more about the efficacy of Gynazole·1.
|
|
| Q:
What drug interactions are associated with Gynazole·1? |
|
|
| Q:
Is there a risk of resistance to Gynazole·1? |
|
A. |
Unlike Diflucan, which has a risk of resistance with repeated use, the
emergence of resistance to butoconazole, the active ingredient in Gynazole·1,
has not been seen. (23) |
|
| Footnote
References |
*Therapeutic efficacy
is based on clinical cure rate (relief of yeast infection symptoms) and
microbiologic cure (pathogen eradication). The therapeutic efficacy rate after
30 days for the one-dose treatment (Gynazole·1) was 62% as compared to 68% for
the 7-day treatment (miconazole-7). The clinical cure rate for miconazole-7 at
8–10 days was 96%. Based on these results, there is no statistically
significant difference between these yeast infection treatments. (1,2)
Diflucan® is a registered trademark of the Pfizer Corporation
Monistat® is a registered trademark of McNeil-PPC.
|
| |
| Important Gynazole•1 Information |
|
|
|
| |
